Santen Pharmaceutical says eye allergy drug meets primary endpoints in Phase III trials

pharmafile | May 11, 2016 | News story | Research and Development, Sales and Marketing Eye Allergy, Santen Pharmaceutical, drug trial, phase III 

Santen Pharmaceutical said late stage trials for its drug to treat an allergic eye condition in children met its primary endpoint. 

The company said Phase III trial for its trial drug for the condition known as vernal keratoconjunctivitis (VKC) showed efficacy and tolerability in patients aged 4–18 years. 

Shigeo Taniuchi, Head of Santen Europe, said: “With these very encouraging results from Vektis, Vekacia is delivering on its promise to provide an innovative and effective treatment that significantly improves outcomes for children with severe VKC.” 

VKC is a severe and recurrent allergic eye condition that mainly affects children (predominantly boys) and young adults, and which results in intense itching photophobia, painful eyes, and potentially even permanent loss of vision. 

The condition is characterised by severe inflammation of the ocular surface, including the conjunctivae and cornea (keratitis). 

Anjali Shukla

Related Content

Biogen Phase III choroideremia study did not meet primary endpoint

Biogen has announced that its investigational gene therapy study for the potential treatment of choroideremia …


Experimental COVID antibody treatment successful in trials

Celltrion has announced positive top-line data for its experimental antibody COVID-19 treatment, with Phase III …


GSK starts Phase III study for severe asthma treatment

GSK has announced today that the first patient has been dosed in part of their …

Latest content